Overview

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study

Status:
Active, not recruiting

Trial end date:
0000-00-00

Target enrollment:
158

Participant gender:
Both

Summary

This study seeks to assess the effectiveness, patient reported outcomes, work productivity and healthcare resource utilization of the interferon-free regimen of Paritaprevir (PTV)/ritonavir (r) - Ombitasvir (OBV), ± Dasabuvir (DSV), ± Ribavirin in chronic hepatitis C (CHC) participants in a real life setting across clinical practice populations.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

AbbVie

Treatments:

Ribavirin

Last Updated:

2016-10-03

Criteria

Inclusion Criteria:

Patients are eligible for observation in this cohort if the following applies:

- Treatment-naïve or -experienced adult male or female patients with confirmed CHC,
genotype 1, receiving combination therapy with the interferon-free ABBVIE REGIMEN ±
RBV according to standard of care and in line with the current local label

- If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line
with the current local label (with special attention to contraception requirements
and contraindication during pregnancy)

- Patients must voluntarily sign and date informed consent prior to inclusion into the
study

- Patient must not be participating or intending to participate in a concurrent
interventional therapeutic trial

Exclusion Criteria:

- Patient must not be participating or intending to participate in a concurrent
interventional therapeutic trial